Association between Trypanosoma cruzi zymodemes and specific humoral depression in chronic chagasic patients.

I' References Apted, F. I. C. (1980). Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the eastern hemisphere. Pharmacology and Therapeutics, 11, 391-413. DoKa, F , Boa, F. Y., Schechter, P. J., Miezan, T. W., Dia, D., Sanon, S. R., de Raadt, P., Haegele, K. D., Sjoerdsma, A. & Konian, K. (1987). Treatment of human late-stage gambiense trypanosomiasis with ordifluoromethylornithine (eflornithine). Efficacy and tolerance in 14 cases of Côte d'Ivoire. AmericanJournal of Tropical Medicine and Hygiene, 37, 525-533. Ginoux, P. Y., Lancien, P.,. Frezil, J. L. & Bissadidi, N. (1984). Les Echecs du tratement de la trypanosomiase à T. gambiense au Congo. Médecine Tropicale, 44,149-154. Gutteridge, W. E. (1985).Existhg chemotherapy and its limitations. British Medical Bulletin, 41, 162-168. Janssens, P. G. & De Muynck, A. (1977). Clinical trials with nifurtimox in African trypanosormasis. Annales de la Société Belge de Médecine Tropicale, 57, 475479. cale, 64, 37-43. Pepin, J., Milord, F., Guern, C. & Schechter, P. J. (1987). Difluoromethvlornithine for arsenoresistant TrvDanosoma bmcei gambihe sleeping sickness. Lancet, ìi, fd31-1433. Van Nieuwenhove, S., Schechter, P. J., Declerq, J., Bone, G., Burke, J. & Sjoerdsma, A. (1985). Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-or-diiluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Transactions of the Royal Socie& of Tropical Medicine and Hygiene, 79, 692-698. WHO (1987). La prévention de la trypanosomiase et la lutte contre cette maladie dans le cadre des soins de santé primaires. Weekly Epidemiological Record, 62, 197-200.